Search Results - "Mackler, Niklas J."

Drug Insight: use of docetaxel in prostate and urothelial cancers by Pienta, Kenneth J, Mackler, Niklas J

“…Taxanes have emerged as a potent class of chemotherapeutic agents in many malignancies, with two taxanes now in clinical use. Their mechanism of action against…”
Get full text

Low-dose versus High-dose Carfilzomib with Dexamethasone (S1304) in Patients with Relapsed-Refractory Multiple Myeloma by Ailawadhi, Sikander, Sexton, Rachael, Lentzsch, Suzanne, Abidi, Muneer H, Voorhees, Peter M, Cohen, Adam D, Rohren, Eric M, Heitner, Stephen, Kelly, Kevin, Mackler, Niklas J, Baer, David M, Hoering, Antje, Durie, Brian, Orlowski, Robert Z

“…Treatment of multiple myeloma has evolved tremendously and optimal utilization of available therapies will ensure maximal patient benefits. We report the…”
Get full text

Phase II trial of paclitaxel, carboplatin and gemcitabine in patients with locally advanced carcinoma of the bladder by Smith, David C, Mackler, Niklas J, Dunn, Rodney L, Hussain, Maha, Wood, David, Lee, Cheryl T, Sanda, Martin, Vaishampayan, Ulka, Petrylak, Daniel P, Quinn, David I, Beekman, Kathleen, Montie, James E

“…This 2-arm phase II multicenter trial was designed to assess the efficacy and toxicity of neoadjuvant paclitaxel, gemcitabine and carboplatin in patients with…”
Get more information

Dose escalation of oral vinorelbine in combination with estramustine in hormone‐refractory adenocarcinoma of the prostate by Mackler, Niklas J., Dunn, Rodney L., Hellerstedt, Beth, Cooney, Kathleen A., Fardig, Judith, Olson, Karin, Pienta, Kenneth J., Smith, David C.

“…BACKGROUND The primary objective of the current study was to identify the tolerable dose level of oral vinorelbine when given in combination with estramustine…”
Get full text

Phase II Evaluation of Oral Estramustine, Oral Etoposide, and Intravenous Paclitaxel in Patients with Hormone-Sensitive Prostate Adenocarcinoma by Mackler, Niklas J, Pienta, Kenneth J, Dunn, Rodney L, Cooney, Kathleen A, Redman, Bruce G, Olson, Karin B, Fardig, Judith E, Smith, David C

“…Abstract Purpose The primary objective of this study was to assess the feasibility and efficacy of administering etoposide/estramustine/paclitaxel in…”
Get full text

Renal Toxicity with Carfilzomib in Multiple Myeloma: Secondary Analysis of SWOG S1304 Comparing Low-Dose Versus High-Dose Carfilzomib by Chakraborty, Rajshekhar, Sexton, Rachael, Lentzsch, Suzanne, Abidi, Muneer H., Voorhees, Peter M., Cohen, Adam D, Rohren, Eric, Heitner, Stephen B., Kelly, Kevin R., Mackler, Niklas J, Baer, David M., Hoering, Antje, Durie, Brian G.M., Ailawadhi, Sikander, Orlowski, Robert Z.

Get full text

Low vs high dose carfilzomib (Cfz) with dexamethasone (Dex) for relapsed/refractory multiple myeloma (RRMM): Results of SWOG S1304 by Ailawadhi, Sikander, Sexton, Rachael, Lentzsch, Suzanne, Abidi, Muneer Hyder, Voorhees, Peter Michael, Cohen, Adam D., Rohren, Eric, Heitner, Stephen, Kelly, Kevin, Mackler, Niklas J., Baer, David M., Hoering, Antje, Durie, Brian G., Orlowski, Robert Z.

“…Abstract only…”
Get full text

B-F1RST: Assessment of novel blood-based biomarkers in patients with first-line advanced or metastatic NSCLC receiving atezolizumab monotherapy by Kim, Edward S., Socinski, Mark A., Dakhil, Shaker R., Mackler, Niklas J., Ikhlaque, Nadeem, Mekhail, Tarek, Volterra, Fabio, El Khoury, Christian Antoine, Schiller, Joan H., Tsai, Michaela L., Hayek, Fadi, Neidhart, Jeffrey D., Hunis, Brian, Hu, Sylvia, Paul, Sarah M., Shames, David S., Phan, See-Chun, Yun, Cindy, Velcheti, Vamsidhar

“…Abstract only TPS9103 Background: The anti–PD-L1 monoclonal antibody atezolizumab inhibits the interaction of PD-L1 with its receptors PD-1 and B7.1, thereby…”
Get full text